🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  2. LN-145

    Iovance Biotherapeutics B.V.

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial

  3. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  4. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial

  5. LUM001

    Mirum Pharmaceuticals International B.V.

    PBC

    phase 2 small molecule completed

    1 trial

  6. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cirrhosis

    phase 2 small molecule terminated

    1 trial

  7. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis (PSC)

    phase 2 small molecule completed

    1 trial

  8. LUM001

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    2 trials

  9. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    3 trials

  10. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial

  11. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD)

    phase 2 small molecule active

    1 trial

  12. Lidocaína B. Braun 20 mg/ml solución inyectable, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio

    The George Institute

    headache pain related to SAH, Spontaneous subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  13. Lifileucel

    Iovance Biotherapeutics B.V.

    Melanoma (Skin Cancer)

    phase 2 mab active

    1 trial

  14. Lifileucel

    Iovance Biotherapeutics B.V.

    Endometrial Cancer

    phase 2 mab active

    1 trial

  15. Lifileucel

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 2 mab completed

    2 trials

  16. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  17. Lumasiran

    Alnylam Netherlands B.V.

    Recurrent Calcium Oxalate Kidney Stone Disease

    phase 2 small molecule terminated

    1 trial

  18. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 2 small molecule completed

    1 trial

  19. Lumasiran

    Alnylam Netherlands B.V.

    PH1

    phase 2 small molecule completed

    1 trial

  20. Lumasiran

    Alnylam Netherlands B.V.

    Haemodialysis

    phase 2 small molecule active

    1 trial

  21. METHYLPREDNISOLONE, METHYLPREDNISOLONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  22. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Biliary Atresia

    phase 2 small molecule completed

    1 trial

  23. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule active

    1 trial

  24. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources